Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2017 · 10-K
Revenue$10.05M$10.05M+686.0% vs Q4 2016 Net Income-$62.49M-$62.49MN/M vs Q4 2016 EPS Diluted-$1.09-$1.09N/M vs Q4 2016 Gross Profit$8,715,000+600.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$47,149,000N/M Free Cash Flowderived-$48,283,000N/M Margins · derivedGross margin86.7%−10.6 pt vs Q4 2016
Operating margin-615.6%+3043.7 pt vs Q4 2016
Net margin-621.6%+3128.4 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 27, 2018 · 58 d after period end